|
gptkbp:instanceOf
|
gptkb:brand
nonsteroidal anti-inflammatory drug
|
|
gptkbp:activeIngredient
|
gptkb:rofecoxib
|
|
gptkbp:approvalYear
|
1999
|
|
gptkbp:approvedBy
|
gptkb:U.S._Food_and_Drug_Administration
|
|
gptkbp:ATCCode
|
M01AH02
|
|
gptkbp:CASNumber
|
162011-90-7
|
|
gptkbp:chemicalFormula
|
C17H14O4S
|
|
gptkbp:developedBy
|
gptkb:Merck_&_Co.
|
|
gptkbp:drugClass
|
nonsteroidal anti-inflammatory drug
|
|
gptkbp:eliminationHalfLife
|
17 hours
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Vioxx
|
|
gptkbp:legalStatus
|
withdrawn
prescription only (before withdrawal)
|
|
gptkbp:marketedIn
|
gptkb:Australia
gptkb:Europe
gptkb:United_States
|
|
gptkbp:mechanismOfAction
|
selective inhibition of cyclooxygenase-2
|
|
gptkbp:notableCase
|
gptkb:Merck_Vioxx_litigation
|
|
gptkbp:patent
|
gptkb:Merck_&_Co.
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:relatedRecall
|
2004 worldwide recall
|
|
gptkbp:retired
|
increased risk of cardiovascular events
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
heart attack
stroke
edema
hypertension
|
|
gptkbp:usedFor
|
osteoarthritis
acute pain
dysmenorrhea
|
|
gptkbp:withdrawn
|
2004
|
|
gptkbp:bfsParent
|
gptkb:MRK
|
|
gptkbp:bfsLayer
|
5
|